FDA approves Alzheimer’s drug, pushing drugmaker’s shares up
The US Food and Drug Administration approved on January 6 Esai and Biogen’s lecanemab, the second-ever treatment for Alzheimer’s disease intended to tackle the root of the condition and slow cognitive decline.